S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
NYSE:NVO

Novo Nordisk A/S - NVO Stock Forecast, Price & News

$126.09
+1.49 (+1.20%)
(As of 12/1/2022 02:03 PM ET)
Add
Compare
Today's Range
$125.21
▼
$126.41
50-Day Range
$95.28
▼
$121.35
52-Week Range
$91.51
▼
$124.60
Volume
30,584 shs
Average Volume
1.33 million shs
Market Capitalization
$285.34 billion
P/E Ratio
37.42
Dividend Yield
0.67%
Price Target
$717.14

Novo Nordisk A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
469.1% Upside
$717.14 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.68mentions of Novo Nordisk A/S in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
22.70%
From $3.26 to $4.00 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

77th out of 1,047 stocks

Pharmaceutical Preparations Industry

34th out of 512 stocks

See Top Rated MarketRank™ Stocks Here
NVO stock logo

About Novo Nordisk A/S (NYSE:NVO) Stock

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock News Headlines

November 30, 2022 | finance.yahoo.com
Novo Nordisk Stock Flashing Renewed Technical Strength
November 30, 2022 | finance.yahoo.com
Novo Nordisk Earns 92 RS Rating, Showing Market Leadership
December 1, 2022 | Investing Trends (Ad)
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
November 28, 2022 | americanbankingnews.com
Novo Nordisk A/S (NYSE:NVO) Receives $717.14 Average Target Price from Analysts
November 24, 2022 | finance.yahoo.com
Should You Invest in Novo Nordisk A/S (NVO) Stock?
November 22, 2022 | reuters.com
Drug maker Novo Nordisk invests $744 mln to expand Danish plant
November 22, 2022 | finance.yahoo.com
Drug maker Novo Nordisk invests $744 million to expand Danish plant
November 22, 2022 | finance.yahoo.com
UPDATE 2-Drug maker Novo Nordisk invests $744 mln to expand Danish plant
December 1, 2022 | Investing Trends (Ad)
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
November 22, 2022 | finance.yahoo.com
Novo Nordisk To Invest Over DKK5B To Add API Production Capacity To Danish Plant
November 22, 2022 | finance.yahoo.com
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
November 22, 2022 | reuters.com
Danish drug maker Novo Nordisk to invest $744 mln to expand facilities in Bagsvaerd
November 22, 2022 | marketwatch.com
Novo Nordisk Invests $743.6 Mln to Expand Clinical Manufacturing Facilities
November 22, 2022 | markets.businessinsider.com
Novo Nordisk To Invest DKK 5.4 Bln To Expand Existing Facilities In Bagsværd, Denmark
November 22, 2022 | finance.yahoo.com
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
November 21, 2022 | businesswire.com
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
November 21, 2022 | finance.yahoo.com
Big Pharmaceutical Firms Target Obesity Treatment
November 8, 2022 | finance.yahoo.com
How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug
November 4, 2022 | seekingalpha.com
Novo Nordisk: Impressive Performance, But Still Pricey
November 4, 2022 | finance.yahoo.com
Why Teva Stock Stumbled Again on Friday
November 4, 2022 | seekingalpha.com
Novo Nordisk A/S (NVO) Q3 2022 Investor Call Transcript
November 4, 2022 | finance.yahoo.com
Novo Nordisk Says the Weight-Loss Drug Shortage Will Be Fixed by Year End
November 4, 2022 | finance.yahoo.com
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
November 2, 2022 | bloomberg.com
Novo Nordisk Shot Helps Teens Lose Weight, New Study Finds
November 2, 2022 | reuters.com
Novo Nordisk sees faster profit growth on diabetes drug Ozempic
November 2, 2022 | msn.com
Why Novo Nordisk A/S Shares Are Shooting Higher Today
November 2, 2022 | seekingalpha.com
Novo Nordisk: Some Changes, But No Changes In Thesis
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Company Calendar

Last Earnings
11/02/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/01/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:NVO
CUSIP
N/A
CIK
353278
Web
www.novonordisk.com
Phone
(454) 444-8888
Fax
45-4449-0555
Employees
45,000
Year Founded
1923

Price Target and Rating

Average Stock Price Forecast
$717.14
High Stock Price Forecast
$900.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+468.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$3.37
Trailing P/E Ratio
37.42
Forward P/E Ratio
38.68
P/E Growth
1.94
Net Income
$7.60 billion
Net Margins
31.57%
Pretax Margin
39.25%
Return on Equity
72.57%
Return on Assets
24.60%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
0.92
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$22.40 billion
Price / Sales
12.74
Cash Flow
$3.78 per share
Price / Cash Flow
33.40
Book Value
$4.58 per share
Price / Book
27.53

Miscellaneous

Outstanding Shares
2,262,970,000
Free Float
2,261,385,000
Market Cap
$285.34 billion
Optionable
Optionable
Beta
0.51

Social Links


Key Executives

  • Mr. Lars Fruergaard JorgensenMr. Lars Fruergaard Jorgensen (Age 56)
    Pres, CEO & Member of Management Board
    Comp: $4.97M
  • Mr. Karsten Munk KnudsenMr. Karsten Munk Knudsen (Age 51)
    Exec. VP, CFO & Member of the Management Board
    Comp: $1.84M
  • Mr. Henrik Ehlers Wulff (Age 52)
    Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board
    Comp: $1.94M
  • Ms. Camilla Sylvest (Age 50)
    Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board
    Comp: $1.84M
  • Ms. Monique Carter (Age 49)
    Exec. VP, Head of People & Organisation and Member of Management Board
    Comp: $1.39M
  • Mr. Maziar Mike Doustdar (Age 52)
    Exec. VP, Head of International Operations & Member of the Management Board
  • Mr. Douglas J. Langa (Age 56)
    Exec. VP, Head of North America Operations & Member of Management Board
  • Mr. Ludovic Helfgott (Age 48)
    Exec. VP, Head of Rare Disease & Member of Management Board
  • Dr. Martin Holst Lange (Age 52)
    Exec. VP, Head of Devel. & Member of the Management Board
  • Dr. Marcus Schindler Ph.D.Dr. Marcus Schindler Ph.D. (Age 56)
    EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NVO Stock - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVO shares.
View NVO analyst ratings or view top-rated stocks.

What is Novo Nordisk A/S's stock price forecast for 2023?

17 Wall Street research analysts have issued 1 year target prices for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $130.00 to $900.00. On average, they anticipate the company's stock price to reach $717.14 in the next twelve months. This suggests a possible upside of 470.8% from the stock's current price.
View analysts price targets for NVO or view top-rated stocks among Wall Street analysts.

How have NVO shares performed in 2022?

Novo Nordisk A/S's stock was trading at $112.00 at the start of the year. Since then, NVO shares have increased by 12.2% and is now trading at $125.63.
View the best growth stocks for 2022 here.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a drop in short interest in October. As of October 31st, there was short interest totaling 2,650,000 shares, a drop of 17.7% from the October 15th total of 3,220,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is currently 1.7 days. Currently, 0.2% of the company's shares are short sold.
View Novo Nordisk A/S's Short Interest.

When is Novo Nordisk A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our NVO earnings forecast.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported $5.27 earnings per share for the quarter, topping the consensus estimate of $0.78 by $4.49. The firm earned $5.65 billion during the quarter, compared to analyst estimates of $5.64 billion. Novo Nordisk A/S had a net margin of 31.57% and a trailing twelve-month return on equity of 72.57%.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 5th. Stockholders of record on Monday, August 15th will be given a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a yield of 1.1%. The ex-dividend date of this dividend is Friday, August 12th.
Read our dividend analysis for NVO.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.67%. The dividend payout ratio is 24.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 20.25% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23.66 billion-$24.23 billion, compared to the consensus revenue estimate of $22.97 billion.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.68%), Jennison Associates LLC (0.48%), Fisher Asset Management LLC (0.41%), Fayez Sarofim & Co (0.23%), BlackRock Inc. (0.21%) and Folketrygdfondet (0.19%).
View institutional ownership trends.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $125.63.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $284.30 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.37 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

The company employs 45,000 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?
The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.

This page (NYSE:NVO) was last updated on 12/1/2022 by MarketBeat.com Staff